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Phenazine 5,10-dioxides (PDOs) are a new class of bioreductive cytotoxins, which could act towards tumours containing hypoxic
regions. The PDOs selective-hypoxic bioreduction was probed in vitro; however, the mechanism of action has not been completely
explained. Besides, PDOs in vivo antitumour activities have not been demonstrated hitherto. We study the mechanism of
hypoxic/normoxic cytotoxicity of PDO representative members. Electron spin resonance is used to confirm •OH production,
alkaline comet assay to determine genotoxicity, and gel electrophoresis and flow cytometry to analyze DNA fragmentation and
cell cycle distribution. Chemically induced rat breast tumours are employed to evaluate in vivo activities. For the most selective
cytotoxin, 7(8)-bromo-2-hydroxyphenazine 5,10-dioxide (PDO1), exclusive hypoxic •OH production is evidenced, while for the
unselective ones, •OH is produced in both conditions (normoxia and simulated hypoxia). In normoxia (Caco-2 cells), PDO1
induces cell-cycle arrest and DNA fragmentation but does not significantly induce apoptosis neither at IC50 nor IC80. No difference
in the comet-assay scores are observed in normoxia and simulated hypoxia being the unselective 2-amino-7(8)-bromophenazine
5,10-dioxide (PDO2) the most genotoxic. The in vivo efficacy with the absence of systemic toxicity of PDO1 and PDO2 is checked
out. Results from this study highlight the potential of PDOs as new therapeutics for cancer.
1. Introduction
Tumours are heterogeneous and contain hypoxic and anoxic
regions, which alter cellular metabolism tending to select
for a more malignant phenotype, which increases mutation
rates, increases expression of genes associated with angio-
genesis and tumour invasion, and is associated with a more
metastatic phenotype of human cancers [1, 2]. By enhancing
metastasis, hypoxia compromises curability of tumours by
surgery. Conversely, the hypoxic cells are associated with
increased resistance to radiation and chemotherapy [3].
Due to the inadequate vascularisation of solid tumours,
drugs do not reach hypoxic cells in adequate concen-
trations. Also, conventional anticancer drugs in clinical
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use are antiproliferative agents that kill dividing cells, by
attacking DNA (synthesis, replication, or processing), being
ineffective in the hypoxic tumours, because these cells are
not dividing rapidly. However, hypoxia has been identified
as an important tool for the specific activation of some
antitumour prodrugs, namely, bioreductive agents [4]. These
prodrugs are inactive in well-oxygenated tissues and are
selectively biotransformed to active cytotoxic species in
hypoxic cells. One of the most studied bioreductive agent is
theN-oxide, tirapazamine (SR4233, Figure 1(a)) [5, 6] which
after one-electron reductive activation releases hydroxyl
free radical (•OH, Figure 1(a)) producing oxidative DNA
damage without covalent binding to DNA and proteins
[7]. Additionally, hybrid compounds that combine an N-
oxide and a ¶-DNA stacking moieties have been described
as enhanced-cytotoxic agents (AQ4N, Figure 1(b)) [8]. In
this sense, we have designed a series of phenazine 5,10-
dioxides (PDOs) as prodrugs that could damage tumour
hypoxic cells through bioreduction, generating free radicals
and DNA damage by intercalation. Some of the developed
PDOs are in vitro hypoxic selective cytotoxins, that is, PDO1
(Figure 1(c)), others are hypoxic partially—or nonselective
cytotoxins, that is, PDO2, PDO3, and PDO4, respectively
(Figure 1(c)), and others are noncytotoxic, that is, PDO5
(Figure 1(c)) [9–12]. Besides, some of the PDOs displayed
in vitro aerobic-antiproliferative activity against Caco-2 cells
[13]. The selective hypoxic reduction and its relationship to
bioreductive activity were proved using enzymatic mammal
systems [14].
To get insight into the mechanism of PDOs hypoxic/oxic
cytotoxicity, herein, we depict a series of experiments.
Electron spin resonance (ESR) experiments, in aerobic—
and anaerobic—metabolic conditions, were done to confirm
the hypothesis that hypoxic-selective PDOs could selectively
produce •OH in system with low oxygen content like
SR4233 (Figure 1(a)). Additionally, PDOs oxidative genetic
damage was evaluated by the modified comet assay after
postdigestion of the cells with formamidopyrimidine-DNA-
glycosylase (FPG) and endonuclease III (EIII). For the best
selective derivative, PDO1, aerobic-cytotoxicity mechanism
on human colorectal adenocarcinoma cell line was studied
analyzing the cell growth inhibition capacity, by MTT assay,
the capability to alter the cell cycle and the possibility
to induce apoptosis, by fluorescence-activated cell sorter
(FACS) and Hoescht analysis, and the capacity to produce
DNA fragmentation by agarose gel electrophoresis. Due to
the ESR experiments showed that some PDOs were able to
produce •OH in normoxia, we also studied the effect of
vitamin C (vitC) on the bioreductive profiles. This study [15]
tried to determine if this antioxidant modifies PDOs bio-
logical behaviours, especially exhibiting a protective action
in normoxic cells. To select the type of tumour for the in
vivo studies, bioreductive profiles against a set of tumour
cells (MCF-7, TK-10, and HT-29) were determined. From
these results, the PDOs were studied in vivo on a chemically
induced model of rat breast tumours, evaluating initially the
systemic toxicity of compounds on healthy animals. The in
vivo antitumour efficacies were evaluated analysing tumours
volumes and histopathologies.
2. Materials andMethods
2.1. Reagents and Cell Culture. PDO1-PDO5 were prepared
according to previous description [9]. All the reagents and
solvents for syntheses and ESR experiments were purchased
from Sigma-Aldrich (St. Louis, Mo, USA). V79 cells (Chinese
hamster lung fibroblasts) were obtained from European
Collection of Animal Cell Cultures, and maintained in
logarithmic growth as subconfluent monolayer by trypsini-
sation and subculture to (1-2) × 104 cells/cm2 twice weekly.
The growth media was Eagle’s Minimal Essential Medium
(EMEM, Gibco, Prat de Llobregat, Barcelona, Spain), con-
taining 10% (v/v) foetal bovine serum (FBS, Gibco, Prat
de Llobregat, Barcelona, Spain) and penicillin/streptomycin
at 100U/100 µg/mL. Caco-2 cells (ATCC/HTB-37, ATCC,
Manassas, VA, USA), were grown in Dulbecco’s Mod-
ified Eagle’s Medium (DMEM, Gibco, Prat de Llobre-
gat, Barcelona, Spain) supplemented with 10% FBS and
1% antibiotic (10,000U/mL penicillin and 10,000Ug/mL
streptomycin, Gibco, Prat de Llobregat, Barcelona, Spain).
Cells were maintained as monolayer cultures at 37◦C
in a humidified atmosphere with 5%CO2. An adequate
number of MCF-7 (human mammary adenocarcinoma,
ATCC HTB-38), TK-10 (human kidney carcinoma, NCI),
and HT-29 (human colon adenocarcinoma, ATCC HTB-38)
cells, were maintained in RPMI-1640 growth media, sup-
plemented with L-glutamine (1%), penicillin/streptomycin
(1%), nonessential amino acids (1%), and 10% (v/v) FBS.
The cultures were maintained at 37◦C and 5%CO2 for
48 h. The absorbance at 540 nm before the treatment was
determined.
2.2. Free Radical Measurements. All ESR experiments were
conducted using a Bruker ECS 106 spectrometer (Bruker
Instruments Inc., Billerica, Mass, USA) in the X band
(9.85GHz) using a rectangular cavity and 50 kHz field
modulation. All the spectra and the hyperfine couplings (to
0.1G) were registered in the same scale and after 15 scans.
2.2.1. Preparation of the Rat Liver Cytosolic Proteins. Livers
were obtained from femaleWistar rats (250–300 g), provided
by the “Centro de Investigaciones Nucleares”, UdelaR (Mon-
tevideo, Uruguay). The animals were allowed food and water
ad libitum. The experimental protocols with animals were
evaluated and supervised by the local Ethics Committee and
the research adhered to the Principles of Laboratory Animal
Care [16]. The animals were sacrificed by cervical dislocation
and the livers, maintained in a ice bath, were perfused in
situ with an ice-cold NaCl (0.9%) solution and washed with
3 volumes of Tris-HCl (0.05M)-sucrose (0.25M) pH =
7.4, then they were sliced and homogenised in a Potter-
Elvehjem glass-Teflon homogeniser. The homogenates were
centrifuged for 30min at 900×g at 4◦C and the supernatant
fraction was centrifuged at 10,000×g for 1 h at 4◦C. The
pellet was discarded and the supernatant fraction was further
centrifuged at 100,000 ×g for 1 h at 4◦C. The cytosolic
fraction, supernatant, was recovered. Protein content was
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Figure 1: (a) The chemical structure and proposed mechanism of action of SR4233. (b) The chemical structure of AQ4N. (c) The chemical
structures and in vitro biological behaviour of PDOs studied here. SF: survival fraction of V-79 cells treated with PDOs at 20 µM; Phypox:
Hypoxic potency, dose which gives 1% of control cell survival in hypoxia; HCR: dose in air divided by the dose in hypoxia giving 1% of
control cell survival.
determined by the bicinchoninic acid assay from Sigma (St.
Louis, MO, USA) as suggested by the manufacturer.
2.2.2. Radical Production Measuring. PDO1-PDO3 or PDO5
(1mM in DMSO), the spin trap N-tert-butyl-α-(4-pyridyl)
nitrone N′-oxide (POBN, 100mM), and rat liver cytosolic
proteins (1mg/mL) in phosphate buffer (0.1M, 1.5mM
EDTA, pH = 7.4) were mixed at 37◦C in the ESR cell
and gassed with nitrogen (simulated-hypoxia) or oxygen
(simulated oxia) for 20min. After that time, the NADPHwas
added. The spectra were recorded after 15 scans. The control
incubations, in both conditions, were without NADPH-
generating system.
2.3. Alkaline Comet Assay. Monolayer V79 cells in expo-
nential growths were trypsinised (Trypsin, Gibco, Prat de
Llobregat, Barcelona, Spain) and suspension cultures were
prepared in 50mL glass flasks: 3.3 × 104 cells/mL in 30mL
of growth media. The glass flasks were topped with rubber
caps perforated with two 21G needles (Microlance, Becton
Dickinson, Fraga, Huesca, Spain) to provide gas inlet and
outlet in order to generate hypoxia and well-oxygenated
conditions. They were placed on a shaking device introduced
in a water bath at 37◦C and were gassed with humidified
air (oxygenated experiment) or with nitrogen (hypoxic
experiment) during all the experiment. Different concen-
trations of PDO1 and PDO2 in 100% dimethylsulfoxide
(DMSO, Panreac, Montcada i Reixac, Barcelona, Spain) were
prepared just before dosing. After 30min of gassing, 200 µL
of each solution were added to reach the following final
concentrations: 10 and 20 µM in oxygenated conditions and
1, 5, and 10 µM in hypoxia. At these concentrations, the
viability is higher than 90%. A control with the solvent was
included under both conditions. After 2 h of treatment, cells
were centrifuged at 175× g and resuspended in 1mL of
growth media. The cell concentration was adjusted to 6.25 ×
105 cells/mL in PBS. Forty microliters were mixed with
130 µL of 1% low-melting-point agarose (Sigma-Aldrich, St.
Louis, Mo, USA) and 80 µL was spread onto microscope
slides (Menzel-Glaser, Braunschweig, Germany) precoated
with 0.5% of normal-melting-point agarose (Sigma-Aldrich,
St. Louis, Mo, USA). Three slides were prepared for each
condition, slides 1, 2, and 3. Glass cover slips (Menzel-
Glaser, Braunschweig, Germany) were placed on the gels,
which were allowed to set at 4◦C. Then, the cover slip was
removed and the cells embedded in agarose were lysed for
1 h by immersion of the slides in 2.5M NaCl, 100mM Na2–
EDTA, 10mM Trizma–HCl, pH = 10 and 1% Triton X-
100 at 4◦C. After that the slides were washed three times
(5min each time) with enzyme buffer (0.1M KCl, 0.5mM
Na2–EDTA, 40mM HEPES-KOH, 0.2mg/mL BSA, pH =
8.0) and incubated for 45min at 37◦C with FPG in the
enzyme buffer—slide 1, or EIII in the enzyme buffer—
slide 2, or with buffer alone—slide 3. Then, the slides were
placed on a horizontal gel electrophoresis tank and the
DNA was allowed to unwind for 40min in freshly prepared
alkaline electrophoresis buffer (300mM NaOH and 1mM
Na2–EDTA, pH > 13). Electrophoresis was run in the same
buffer for 30min at 25V (about 0.8 V/cm across the gels
and approximately 300mA) in an ice bath condition. The
slides were rinsed three times (5min each time) with 400mM
Trizma (pH = 7.5) to neutralize the excess alkali. Then,
the slides were washed in water and drained overnight.
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Gels were stained with 25 µL of 1 µg/mL DAPI (Sigma–
Aldrich, St. Louis, Mo, USA), covered with a cover slip
and coded before microscopic analysis. DAPI stained nuclei
were evaluated with a Nikon Eclipse TE 300 fluorescence
microscope (Nikon, Tokyo, Japan). A total of 100 comets on
each gel were visually scored and classified as belonging to
one of five classes according to the tail intensity. Each comet
class was given a value between 0 and 4: (0) = no damage
and (4) =maximum damage. The total comet score (tcs) was
calculated by the following equation: (percentage of cells in
class 0× 0) + (percentage of cells in class 1× 1) + (percentage
of cells in class 2 × 2) + (percentage of cells in class 3 ×
3) + (percentage of cells in class 4 × 4). Consequently, the tcs
was in the range from 0 to 400. Controls were included, only
solvent for negative and treatment with hydrogen peroxide
(50 µM) during 5min on ice for positive one. Experiments
were performed in triplicate.
2.4. Oxic-Studies on Caco-2 Cells
2.4.1. Antiproliferative Activity. The assay was performed
using previously described method slightly modified [17].
Samples containing 200 µL cell suspension (2× 104 cells/mL)
were plated in 96-well-flat-bottomed microtiter plates. After
adherence of the cells within 24 h of incubation at 37◦C,
PDO1 and PDO2 at doses ranging from 1 µM to 1000 µM
were added to different wells (3-4 per concentration). After
additional incubation time (24, 48, and 72 h) at 37◦C in
a humidified incubator with 5% CO2, MTT dissolved in
PBS and sterile filtered was added to all the wells at a final
concentration of 1mg/mL. Following 1 h of incubation, the
generated formazan was dissolved with 100 µL DMSO per
well. The optical density was measured using an ELISA plate
reader (Merck ELISA system MIOS version 3.2.) at 550 nm.
The concentrations that caused 50 and 80% inhibition of cell
growth (IC50 and IC80) were calculated.
2.4.2. Cell Cycle Analysis. Cell cycle was assessed through
flow cytometry by using a FACS. Cells were cultured in
6-well flat bottomed microtiter plates containing 2mL of
cell suspension. The number of cells was determined by
calculation according to the number of cells/wells in 96-
well plates (582,000 cells). After 24 h of incubation at 37◦C
with 5% CO2, PDO1 was added at IC50 dose. Following 24 h
of incubation, cells were harvested by mild trypsinisation,
collected by centrifugation and stained in Tris buffered
saline for 1 h at 4◦C. FACS analysis was carried out at
488 nm in an Epics XL flow cytometry (Coulter Corporation,
Hialeah, Fla, USA). Data from 12,000 cells were collected and
analysed using Multicycle program (Phoenix Flow Systems,
San Diego, Calif, USA). All experiments were performed in
triplicate and repeated three times.
2.4.3. Assessment of Apoptosis. Apoptosis was assessed using
Annexin V-fluorescein isothiocyanate (FITC) kit binding
assay and analyzed by FACS. Cell culture and treatment with
PDO1 was carried out as described in cell-cycle analysis
section. Thereafter, cells were resuspended in binding buffer
(10mM Hepes/NaOH, pH = 7.4, 140mM NaCl, 2.5mM
CaCl2). Annexin V-FITC (Bender System Kit) was added
according to the product insert and incubated for 30min
at room temperature in the dark. One min before FACS
analysis, propidium iodide (PI) was added at a concentra-
tion of 20 µg/mL. Approximately 500.000 viable cells were
counted to assess apoptosis. Experiments were performed in
triplicate.
2.4.4. Apoptosis Determination with Bisbenzimide Hoechst, to
Evaluate Chromatin Condensation. Apoptosis was assessed
using bisbenzimide Hoechst and analyzed by Fluorescence-
Microscope. Cells were cultured in 6-well flat bottomed
microtiter plates containing 2mL of cell suspension. The
number of cells was determined by calculation according
to the number of cells/wells in 96-well plates (12,000).
After 24 h of incubation at 37◦C with 5% CO2, PDO1 was
added at its respective IC50 and IC80 doses. Following 24 h
of incubation in the absence or presence of the indicated
compound, cells were harvested by mild trypsinisation,
collected by centrifugation and fixed with paraformaldehyde
at 3.7% for 10min at −20◦C. Cells were washed with PBS,
centrifuged at 2500 rpm for 5min, Triton-X100 at 0.5% was
added for 5min at 4◦C and cells were stained with 50 ng/mL
Hoechst 33258 dye for 15min and then placed onto slides,
coverslips were mounted with Mowiol 4–88. Chromatin
condensation was visualized by fluorescence microscopy.
2.4.5. DNA Fragmentation Study. DNA fragmentation was
determined using “Real Pure Extraction Kit”. In short, 2 ×
106 cells/well were cultured in 100-mm plates and treated
for 24 h with PDO1 at IC50 dose. Chromosomal DNA
was isolated (Real, Durviz, Valencia, Spain) and ladder
formation was analysed in a 1% agarose gel visualizing
with ethidium bromide staining. Staurosporine (10 µM) was
used as positive control. This assay was performed on four
separate occasions for statistical analysis [18].
2.5. Clonogenic Bioreductive Assays. Monolayers of cells
(V79, MCF-7, TK-10, or HT-29) in exponential growth were
trypsinised, and suspension cultures were set up in 50mL
glass flasks: 2 × 104 cells/mL in 30mL of the corresponding
growthmedia. The glass flasks were submerged and stirred in
a water bath at 37◦C, where they were gassed with humidified
air or pure nitrogen. Treatment [19]: compounds solutions
were prepared just before dosing. Stock solutions, 150-fold
more concentrated, were prepared in pure DMSO (Aldrich,
St. Louis, Mo, USA) or sterilized distilled water. Thirty min
after the start of gassing, 0.2mL of the stock compound
solution was added to each flask, two flasks per dose. In
every assay, there was one flask with 0.2mL of DMSO
(negative control). In the assays with vitC, after 5min of
gassing the cells suspension, with air or nitrogen, 100 µL of
vitamin solution was added to reach the same concentrations
that the studied PDOs and 25min pretreatment before
compounds addition was done. Cloning: after 2 h exposure
to the compound, the cells were centrifuged and resuspended
in plating medium. Cell numbers were determined with
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a haemocytometer and 102–103 cells were plated in 6-
well plates to give a final volume of 2mL/30mm of well.
Plates were incubated at 37◦C in 5% CO2 during 7 days,
for V79, or 14 days, for MCF-7, TK-10, and HT-29, and
then stained with aqueous crystal violet. Colonies with
more than 64 cells were counted. The plating efficiency
(PE) was calculated by dividing the number of colonies
by the number of cells seeded. The percent of control-cell
survival for the compound-treated cultures (SFnormoxia
and SFhypoxia) was calculated as PE-treated/PE-control 100.
The compounds were tested at different doses in duplicate
flasks both in normoxic and hypoxic conditions.
2.6. In Vivo Studies
2.6.1. Animals. Specific pathogen-free 180-day-old adult (for
maximum tolerated doses (MTD) studies and toxicity in
healthy animals studies) or 60-day-old adult (for in vivo
tumour studies) female Sprague-Dawley rats were purchased
from Centro de Investigaciones Nucleares-Universidad de
la Repu´blica (Montevideo, Uruguay). Rats were housed
in sterile individually ventilated cages; food and water
were provided ad libitum, in accordance with the standard
operating procedures set down in SI 17/94 of the European
Union. Rats were acclimatised for 1 week before the initiation
of any in vivo experiments. Animals were sacrificed by
cervical dislocation if found to be in distress (hunching,
failure to groom, etc.) or if tumour volume exceeded 10% of
mouse bodyweight. All experiments were performed accord-
ing to the Local Animal Ethics Committee (Universidad
de la Repu´blica Ethical Committee, Montevideo, Uruguay)
guidelines for animal experimentation.
2.6.2. Formulation of Compounds for In Vivo Trials. PDO1
and PDO2 were suspended in sterile saline: Tween80 (4 : 1)
(vehicle solution) immediately prior to injection. These
preparations were made under aseptic conditions and in
all cases suspensions were obtained by shaking under
ultrasound conditions.
2.6.3. In Vivo Dose Treatment Determination. In order to
determine the in vivo dose with the minimum associated-
toxicity first at all the MTDs (dose giving 20% weight
loss within 3 days of a single ip administration) for
PDO1 and PDO2 were determined [19]. Consequently,
three nontumour-bearing animals per dose level were
injected intraperitoneally with a single dose of compound,
at 60, 120, or 300mg/kgb.w. Animals were weighed and
observed daily for alterations in skin, physical aspect,
activity and faeces aspect. After that, nontumour-bearing
animals were treated intraperitoneally, at a dose equivalent
to MTD/6, according to schedule showed in Figure 1S
(see Appendix. Supplementary data, which is located at
doi: 10.5402/2011/314209 ). Animals were sacrificed at the
experimental end point (Figure 1S), the organs (lung, kidney,
liver, spleen, heart, and intestine, maintained in aqueous
formalin solution (10%)) for further histological studies
were obtained by autopsy and blood for biochemical and
haematological studies was drawn by sectioning the subcla-
vian artery. Biochemical and haematological determinations
were done immediately or nomore than 24 h post-extraction
maintaining the blood in EDTA or heparin at 0◦C.
2.6.4. Tumour Model: Chemically Induced Rat Mam-
mary Tumours. Twenty-twenty five rats were treated with
5mg/kgb.w. of N-nitrosomethylurea (NMU, Sigma-Aldrich,
St. Louis, MO, USA, dissolved in acidified saline) by tail-
vein injection at 60, 90, and 120 days of age [20]. Animals
were palpated twice a week 60 days after the last NMU
administration in order to record the presence, location, size,
and date of detection for all tumours. Induction efficiency of
50% was obtained.
2.6.5. In Vivo Antitumour Studies. When the tumours
reached approximately 4mm in diameter the rats were
randomly divided into three groups (untreated animals,
PDO1-, or PDO2-treated). The treatment groups received
an ip injection of PDOs, at a dose equivalent to MTD/6;
once daily according to schedule showed in Figure 1S (see
Appendix. Supplementary data). Control rats received in the
same schedule only vehicle solution. Tumour growth was
measured with a sterile calliper. The long (L) and short (S)
axes were recorded, and tumour volume (V) was calculated
using the following equation as described previously [21]:
V =
(
S2 × L)
2
. (1)
Regarding statistical analysis, Student’s t-test was conducted
in a comparison between two groups.
Animals were sacrificed at the experimental end point
(Figure 1S), the organs (lung, kidney, liver, spleen, heart,
and intestine, maintained in aqueous formalin solution
(10%)) and tumours for further histological studies were
obtained by autopsy and blood for biochemical and haema-
tological studies was drawn by sectioning the subclavian
artery. Biochemical and haematological determinations were
done immediately or no more than 24 h after extraction
maintaining the blood in EDTA or heparin at 0◦C. Sections
from organs and tumours were fixed in 10% neutral buffered
formalin and embedded in paraffin. Blocks were sectioned
and fixed on slides to be evaluated histopathologically.
3. Results and Discussion
In order to probe that the PDO bioreduction is associ-
ated to •OH production and to know whether it occurs
according to compounds selectivity profiles, some PDOs
were metabolised under normoxia and simulated hypoxia
and ESR spectra were acquired. Therefore, one selective,
PDO1, two partially selective, PDO2 and PDO3, and one
noncytotoxic derivative, PDO5 (Figure 1(c)), were included
in this study. Except for compounds PDO1 in normoxia
and PDO5 in both conditions the spectra show a double
triplet signal (Figure 2) with hyperfine splitting of aH =
2.9 and aN = 16.0G, which pattern is attributed of the
spin trap(POBN)-•OH adduct. Spin trap-ESR experiments
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Figure 2: ESR studies of PDOs in bioreductive system (rat liver
cytosolic proteins, 1mg/mL, +NADPH). ESR spectra of PDOs
(1mM, treated as indicated in Material and methods section) were
recorded in presence of the spin trap POBN (100mM). Number of
scans: 15.
clearly demonstrated PDOs were able to release •OH in pres-
ence of bioreductive systems finding that non selective and
cytotoxic derivative, that is, PDO2, produces it under both
conditions contrary non active derivative, that is, PDO5,
shows no free radical production (no signal in the ESR spec-
trum). While the in vitro hypoxic selective cytotoxin PDO1
releases •OH only under simulated hypoxia. For PDO2 and
PDO3 in normoxia the identified •OH could be the result of a
“futile redox cycling”, where the produced superoxide radical,
O•−2 , via spontaneous dismutation gives H2O2 that could
be reduced to the •OH free radical. These results confirm
that cytotoxic selectivity could be due to the selective radical
species generation during the bioreduction process under
hypoxic conditions as it is described for SR4233 [7].
To evaluate the role of •OH on the DNA damage
we checked, using alkaline comet assay, whether PDO1
and PDO2 were able to generate DNA strand breaks
and oxidative DNA damage. This last phenomenon could
be probed by alkaline comet assay using two enzymes
[23], that is, FPG and EIII. FPG is involved in the first
step of base excision repair to remove specific modified
bases from DNA excising mainly 2,6-diamino-4-hydroxy-
5-N-methylformamidopyrimidine and 8-oxo-G. EIII nicks
DNA at sites of oxidised-pyrimidines. Figure 3 shows the
comet assay results obtained with PDO1 and PDO2 in
the different experimental conditions. Under simulated-
hypoxia the treatment with PDO1 during 2 h (Figure 3(a))
increased moderately the total comet score (tcs) of V79 cells
comparing to hypoxic untreated cells (C(−), Figure 3(a))
however lower than the tcs of positive control (C(+): H2O2,
50 µM, during 5min on ice) at all the studied doses.
Additionally, PDO1 was less genotoxic in both conditions
than previous studied quinoxaline dioxide [15]. No dose
dependence was observed either in simulated hypoxia or in
normoxia. Interestingly, according to a significant increase
in the tcs when the V79 cells were digested with FPG,
PDO1 could produce genotoxicity in hypoxia by production
of 8-oxo-G. No differences were found between treatments
with and without EIII showing absence of hypoxic-PDO1
oxidizing capability on pyrimidines. On the other hand,
PDO2 produced (Figure 3(b)), in a dose-dependent manner
and in both conditions, higher tcs than negative control and
PDO1 being the results more notorious in simulated hypoxic
conditions. There were differences between the hypoxic tcs
when the digestions were done with both FPG and EIII and
without them showing PDO2 hypoxic genotoxicity could be
the result not only of the production of oxidised-purines
(8-oxo-G) but also oxidised pyrimidines. These results indi-
cate PDO1 and PDO2 promote in hypoxia DNA-oxidative
damage yielding oxidised purines or oxidised purines and
pyrimidines, respectively, like SR4233. In agreement with
the ESR experiments in normoxia, PDO2 produced higher
DNA-strand breaks than PDO1.
For the best selective derivative, that is, PDO1 (better
in vitro Phypox and HCR, Figure 1(c)), aerobic-cytotoxicity
mechanism on human colorectal adenocarcinoma cell line,
Caco-2, was studied. According to our previous results PDO1
showed low oxic cytotoxicity [9], and this, according to
results herein depicted, could be related to DNA damage
(Figure 3(a)) and not to •OH production (Figure 2).
Caco-2 growth inhibition capacity of derivative PDO1
was studied by MTT assay, its capability to alter the cell
cycle and the possibility to induce apoptosis were examined
using fluorescence-activated cell sorter (FACS) and Hoescht
analysis, and its capacity to produce oxic DNA fragmentation
was analyzed by agarose gel electrophoresis.
As indicated by the IC80, PDO1 was less Caco-
2-antiproliferative agent than PDO2 in oxic conditions
(Figure 4(a)). PDO1 was able to induce an arrest in G2/M
cell cycle phase, after 24 h and at IC50 dose (Figure 4(b)),
which led cells to necrosis confirmed by Annexin V analysis.
However, PDO1 also produced apoptotic cells at IC50 and
IC80 doses, confirmed by Hoechst (data not shown) and
by the appearance of DNA-ladder pattern (Figures 4(c)–
4(e)). These experiments highlight the relevance of PDO1 as
potential drug in overcoming cancer.
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Figure 3: Alkaline comet assay analysis on V79 cells incubated with the studied compounds in different conditions and doses, expressed as
cells in five different classes (0–5) and quantified as Collins et al. [22]. C(−): negative control (only solvent); C(+): positive control (treatment
with hydrogen peroxide, 50 µM, during 5min on ice).
Table 1: PDO cytotoxic effects in simulated hypoxia and normoxia on different conditions and cellular systems.
Comp. Dose (µM)
SFa,b,c in simulated hypoxia SFa,b,c in normoxia
−vitCd +vitC −vitC +vitC
PDO2 5 3 ± 1 0 ± 0 87 ± 5 83 ± 4
PDO3 20 11 ± 2 8 ± 2 61 ± 3 74 ± 2
PDO4 5 4 ± 1 0 ± 0 67 ± 3 80 ± 5
Comp. Dose (µM) SFhypoxiaa,b SFoxiaa,b
20 0 ± 0 5 ± 1
MCF-7
PDO2 5 0 ± 0 34 ± 3
20 0 ± 0 26 ± 3 TK-10
20 0 ± 0 18 ± 2 HT-29
a
SF: survival fractions (%). bValues are means of two different experiments. The assays were done by duplicate and using at least three repetitions, and standard
errors were not greater than 2 % for most assays. cUsing V79 cells. dvitC: vitamin C (pretreatment during 25min with equimolecular amount of vitamin).
Due to the ESR experiments showed that PDO2 and
PDO3 were able to produce •OH in normoxia, we studied
the effect of vitC on their V79-hypoxic and normoxic
cytotoxicities. Therefore, to see whether vitC had protective
activity in oxygenated systems and prooxidant activity in
hypoxic ones we performed an in vitro bioreductive study
preincubating the cells with vitC 25min before the incor-
poration of PDO2, PDO3, or PDO4 into to the milieu.
PDO3 and PDO4 selective cytotoxic profiles were modestly
modified to most selective behaviours in presence of vitC
(Table 1) which apparently scavenges reactive oxygen radicals
in normoxia. However, in hypoxic conditions, and also
for PDO2, vitC potentiates compounds cytotoxicity in V79
cells [24], like it was described previously for SR4233 [25].
This information could be used for future cancer treatment
schedules.
To select the type of tumour for in vivo studies, hypoxic
and normoxic cytotoxicity against a set of tumour cells,
MCF-7, TK-10, and HT-29, were performed with the
hypoxic partially selective cytotoxins PDO2. From these
studies (Table 1), it could be seen partially selective cytotoxic
profiles on the three studied tumour cells, like in V79 ones,
showing the major cytotoxicity against human breast cancer
cells (MCF-7).
After the demonstration that hypoxic selective PDO1
induce some degree of apoptosis in oxia and hypoxic non-
selective PDO2 is not just specific for any of the studied
tumour cells but awfully toxic for MCF-7, we next sought to
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Figure 4: (a) IC50 and IC80 of PDO1 and PDO2 on Caco-2 cells after 24, 48, and 72 h incubation. (b) Percentage of distribution in different
phases of cell cycle of untreated (!) and treated Caco-2 cells after 24 h with PDO1 at respective IC50 (") and IC80 ("). (c) Percentage of early
and late apoptotic and necrotic cells assessed by flow cytometry analysis of Annexin V-FITC staining and PI accumulation after exposure of
Caco-2 cells to PDO1 at respective IC50 and IC80 after 24 h of incubation. (d) Apoptotic peaks detected by flow cytometry in treated Caco-2
cells after 24 h incubation with untreated (left) and PDO1-treated (right) at respective IC80. (e) Agarose gel electrophoresis analysis of DNA
from Caco-2. Cells were incubated in the absence of substances (CT) or treated with PDO1 at IC50 or staurosporine (10 µM) (C+) for 24 h.
determine the effects of both compounds in an in vivo breast-
cancer model. We selected the model of NMU chemically
induced breast tumours because these tumours have hypoxic
regions [26], and consequently, it is appropriate to study the
in vivo behaviour of hypoxic cytotoxin PDO1.
Initially, we confirmed that PDO1 and PDO2 did not
adversely affect healthy animals being the MTD higher than
300mg/kgb·w. (Table 1S, Appendix. Supplementary data).
Higher doses were not assayed due to solubility prob-
lems. Both derivatives have very good values of MTD
in comparison to values in mice for similar dioxides
(quinoxalines and SR4233) [19, 27]. Also, four-week treat-
ments were performed according to the selected schedule
(Figure 1S, Appendix. Supplementary data) using a dose of
50mg/kgb·w/day equivalent to MTD/6. In this condition,
animals showed no alteration of behaviour during the
study and the mortalities were 0%. Organs histology (data
not shown) and biochemical and haematological findings
(Table 2S, Appendix. Supplementary data) showed this treat-
ment did not affect the healthy and strength of the animals.
Secondly, treatments with PDO1 and PDO2, according
to schedule shown in Figure 1S (Appendix. Supplementary
data), to breast-tumour-bearing animals resulted in strong
and significant decreases in tumour size indicating that both
PDO1 and PDO2 significantly impeded tumour growth
(Figure 5(a)). However, in untreated animals, the tumour
grew progressively. Whereas for PDO2 the size tumours
diminution, respect to day 0, was evident at day 20th for
PDO1 was manifested at the treatment’s beginning. During
PDO1 and PDO2 treatments no alteration of the animals
was observed and mortality was 0%. From the necropsies, at
experimental end point day 29th, were obtained the tumours
(Figure 5(b)) and organs. The histopathologic studies of
PDO1-treated tumours showed absence of necrotic zones
and good vascularisation (arrows in Figure 5(c)), while
the untreated tumours had full necrosis areas (circle in
Figure 5(c)). In addition, the size reduction could be the
result of the tumour compartmentalisation as result of
the collagen from the tumour capside (Figure 5(d)). This
compartmentalisation could produce tumour packing and
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Figure 5: Antitumour effects of PDO1 and PDO2. (a) Tumour growth was measured every week and the change in the size was expressed
respect to day 0 (beginning of the treatment). Results are expressed as the mean (n = 4 per group, statistical analysis was performed using the
Student’s unpaired t-test, ∗∗P < .01). Rats were killed on day 29, organs and (b) tumours were removed comparing size and weight of treated
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tumours demonstrated: (c) absence of necrosis and vascularisation (arrows) for PDO1 treated (left) and necrosis (circle) for untreated;
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differential infiltration of lymphocytes and eosinophils (arrows), significant immune response for PDO1-treated (left) and irrelevant for
untreated (left).
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further fragmentation. Moreover, the untreated tumours
showed local metastasis and absence of compartmentalisa-
tion phenomenon (Figure 5(d)). Additionally, in the PDO1-
treated tumours a desmoplastic and peritumour reaction was
observed with infiltration of lymphocytes and eosinophils
(arrows in Figure 5(e)). This high infiltration could be
indicating an enhanced of the immune response against the
tumour. The untreated tumour showed a lower infiltration
(arrows in Figure 5(e)). Table 3S (Appendix. Supplementary
data) summarises these observations.
In conclusion, we completed the information related to
PDOs mechanism of cytotoxicity and in vivo behaviours.
The PDOs acted as bioreductive agents by hypoxic •OH
free radical production oxidative-damaging DNA. Clearly,
the ESR studies showed that the PDOs bioreduction,
concomitantly with the generation of the corresponding
reduced analogues [14], releases •OH free radical. The
selective hypoxic cytotoxin PDO1 only produces this species
in simulated hypoxia while the non- or poorly selective
cytotoxins, PDO2 and PDO3, produce it in both conditions.
The in vivo results could be indicating that PDO1 and
PDO2 reach the tumour on a very good concentration
and after the bioreduction process drugs remain in the
tumour cells. This could increase the possibility of cytotoxic
events and also trigger action killing the surrounding well
oxygenated cells. Future studies investigating the activity
of the PDOs in combination with vitC, and with other
anticancer agents in vivo are planned, as are other tumour
models and dosing-schedules. Also a combined treatment
of both compounds could be performed considering the
immune response activation produces by PDO1 and the
excellent size tumour reduction provides by PDO2.
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